X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11967) 11967
Magazine Article (48) 48
Book Chapter (45) 45
Web Resource (7) 7
Book Review (5) 5
Conference Proceeding (5) 5
Book / eBook (4) 4
Dissertation (4) 4
Newspaper Article (4) 4
Streaming Video (4) 4
Newsletter (3) 3
Transcript (2) 2
Publication (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10109) 10109
bone density conservation agents - therapeutic use (7712) 7712
female (6624) 6624
osteoporosis (4564) 4564
male (4115) 4115
aged (3682) 3682
middle aged (3523) 3523
diphosphonates - therapeutic use (3406) 3406
osteoporosis - drug therapy (2682) 2682
animals (2550) 2550
endocrinology & metabolism (2350) 2350
bone density - drug effects (2083) 2083
postmenopausal women (2076) 2076
bisphosphonates (2007) 2007
orthopedics (1962) 1962
fractures (1914) 1914
bone density conservation agents - adverse effects (1857) 1857
medicine & public health (1856) 1856
risk factors (1799) 1799
bone density conservation agents - administration & dosage (1763) 1763
aged, 80 and over (1676) 1676
treatment outcome (1676) 1676
osteoporosis, postmenopausal - drug therapy (1604) 1604
bone density (1596) 1596
rheumatology (1564) 1564
zoledronic acid (1544) 1544
adult (1496) 1496
alendronate (1496) 1496
bone-mineral density (1373) 1373
care and treatment (1366) 1366
bone density conservation agents - pharmacology (1348) 1348
bones (1331) 1331
research (1277) 1277
drug therapy (1269) 1269
women (1257) 1257
endocrinology (1223) 1223
health aspects (1162) 1162
risk (1160) 1160
diphosphonates - adverse effects (1137) 1137
prevention (1088) 1088
analysis (1079) 1079
therapy (1054) 1054
oncology (1020) 1020
imidazoles - therapeutic use (985) 985
diphosphonates - administration & dosage (948) 948
bone mineral density (929) 929
density (918) 918
alendronate - therapeutic use (904) 904
fractures, bone - prevention & control (887) 887
rats (884) 884
bone (879) 879
pharmacology & pharmacy (862) 862
bone neoplasms - secondary (852) 852
medicine, general & internal (796) 796
double-blind (782) 782
osteoporotic fractures - prevention & control (777) 777
denosumab (776) 776
cancer (773) 773
retrospective studies (766) 766
surgery (753) 753
osteoporosis - prevention & control (737) 737
mice (735) 735
bisphosphonate (724) 724
postmenopausal osteoporosis (699) 699
bone neoplasms - drug therapy (691) 691
vitamin d (678) 678
vitamin d - therapeutic use (672) 672
osteoporosis - complications (671) 671
mineral density (667) 667
abridged index medicus (666) 666
stem cells (646) 646
hip fracture (634) 634
internal medicine (633) 633
fracture (627) 627
teriparatide - therapeutic use (616) 616
absorptiometry, photon (612) 612
time factors (612) 612
follow-up studies (606) 606
medicine, research & experimental (606) 606
diphosphonates (590) 590
dentistry, oral surgery & medicine (576) 576
risedronate (570) 570
bone and bones - drug effects (569) 569
dentistry (568) 568
complications and side effects (564) 564
in-vitro (543) 543
drug administration schedule (540) 540
prospective studies (538) 538
bone remodeling - drug effects (523) 523
diphosphonates - pharmacology (522) 522
cell biology (521) 521
diagnosis (521) 521
calcium (520) 520
vertebral fractures (520) 520
disease models, animal (510) 510
dosage and administration (505) 505
osteoporosis - diagnosis (501) 501
osteoporosis - physiopathology (499) 499
fractures, bone - etiology (496) 496
teriparatide (496) 496
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11374) 11374
Japanese (322) 322
German (168) 168
French (134) 134
Spanish (70) 70
Chinese (30) 30
Russian (29) 29
Danish (26) 26
Dutch (24) 24
Italian (20) 20
Hungarian (19) 19
Croatian (18) 18
Polish (18) 18
Czech (13) 13
Portuguese (8) 8
Ukrainian (7) 7
Norwegian (6) 6
Finnish (4) 4
Hebrew (4) 4
Serbian (4) 4
Slovak (4) 4
Swedish (3) 3
Turkish (2) 2
Arabic (1) 1
Bulgarian (1) 1
Georgian (1) 1
Lithuanian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2009, Volume 361, Issue 8, pp. 745 - 755
...B ligand, on bone mineral density and fractures in such men. Use of denosumab was associated with increased bone mineral density at all sites and reduction in the incidence of new vertebral fractures... 
ZOLEDRONIC ACID | FRACTURE | MEDICINE, GENERAL & INTERNAL | PLACEBO | BONE-MINERAL DENSITY | RISK | COMPLICATIONS | RANDOMIZED CONTROLLED-TRIAL | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | ALENDRONATE | Lumbar Vertebrae - injuries | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Male | Osteoporosis - drug therapy | Prostatic Neoplasms - physiopathology | Bone Remodeling - drug effects | Incidence | Antibodies, Monoclonal, Humanized | Spinal Fractures - prevention & control | RANK Ligand - pharmacology | Injections, Subcutaneous | Aged, 80 and over | RANK Ligand - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Lumbar Vertebrae - physiology | Prostatic Neoplasms - drug therapy | RANK Ligand - adverse effects | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Prostatic Neoplasms - surgery | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Denosumab | Bone Density Conservation Agents - pharmacology | Orchiectomy | Bone Density - drug effects | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Fractures, Bone - prevention & control | Osteoporosis | Bone density | Prostate cancer | Older people | Men | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 7, pp. 679 - 691
...% of early breast cancers, are unknown. 7 The combination of ovarian suppression with the use of gonadotropin-releasing hormone analogues and tamoxifen is a standard... 
BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | METASTASES | DELTA T-CELLS | RECEPTOR | ADJUVANT THERAPY | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 15, pp. 1417 - 1427
... is an antiresorptive agent commonly used as first-line therapy for osteoporosis. In a trial involving postmenopausal women with prevalent fractures, the risks of vertebral... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | BONE-MINERAL DENSITY | VERTEBRAL FRACTURES | DISEASE | AORTA | RANDOMIZED-TRIAL | RISK | STRENGTH | POSTMENOPAUSAL WOMEN | SCLEROSTEOSIS | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk | General & Internal Medicine
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 5, pp. 412 - 420
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 61 - 73
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 9999, pp. 1147 - 1155
Journal Article